We’re performing maintenance on our Claims Management System. As a result, some of these online services will not be available on Saturday, February 29 from 7:30 a.m. to 2:00 p.m. We apologize for any inconvenience.
Bevacizumab in Addition to Carboplatin-Pemetrexed in Treating Peritoneal Mesothelioma
To determine what the benefit is, if any, of adding bevacizumab to the combination treatment of carboplatin-pemetrexed to treat patients diagnosed with advance peritoneal mesothelioma.
Publication Date: Dec 2015
File type: PDF (260 KB) Asset type: Guide